Clinical Research Directory
Browse clinical research sites, groups, and studies.
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: Guangzhou JOYO Pharma Co., Ltd
Summary
Evaluating Sufenidone (SC1011) in IPF patients for efficacy and safety. Includes screening, treatment, and follow-up, with FVC decline and health checks.
Official title: A Randomized, Double-blind, Placebo-controlled Phase II/III Trial Evaluating the Efficacy and Safety of Sufenidone (SC1011) Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF).
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
210
Start Date
2023-06-06
Completion Date
2027-12-31
Last Updated
2024-11-19
Healthy Volunteers
No
Conditions
Interventions
SC1011
Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
Placebo comparator
Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
Locations (1)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China